Gemcitabine for relapsed or resistant lymphoma

D. G. Savage, S. A.J. Rule, M. Tighe, T. J. Garrett, M. W. Oster, R. T. Lee, J. Ruiz, D. Heitjan, M. L. Keohan, M. Flamm, S. A. Johnson

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma. Patients and methods: Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma. Results: The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non- hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months. Conclusions: Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.

Original languageEnglish (US)
Pages (from-to)595-597
Number of pages3
JournalAnnals of Oncology
Volume11
Issue number5
DOIs
StatePublished - Jul 15 2000

Fingerprint

gemcitabine
Lymphoma
Therapeutics
Disease Progression
Pharmaceutical Preparations
Mantle-Cell Lymphoma
Hematologic Neoplasms
Hodgkin Disease
Sepsis

Keywords

  • Gemcitabine
  • Hodgkin's disease
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Savage, D. G., Rule, S. A. J., Tighe, M., Garrett, T. J., Oster, M. W., Lee, R. T., ... Johnson, S. A. (2000). Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology, 11(5), 595-597. https://doi.org/10.1023/A:1008307528519

Gemcitabine for relapsed or resistant lymphoma. / Savage, D. G.; Rule, S. A.J.; Tighe, M.; Garrett, T. J.; Oster, M. W.; Lee, R. T.; Ruiz, J.; Heitjan, D.; Keohan, M. L.; Flamm, M.; Johnson, S. A.

In: Annals of Oncology, Vol. 11, No. 5, 15.07.2000, p. 595-597.

Research output: Contribution to journalArticle

Savage, DG, Rule, SAJ, Tighe, M, Garrett, TJ, Oster, MW, Lee, RT, Ruiz, J, Heitjan, D, Keohan, ML, Flamm, M & Johnson, SA 2000, 'Gemcitabine for relapsed or resistant lymphoma', Annals of Oncology, vol. 11, no. 5, pp. 595-597. https://doi.org/10.1023/A:1008307528519
Savage DG, Rule SAJ, Tighe M, Garrett TJ, Oster MW, Lee RT et al. Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology. 2000 Jul 15;11(5):595-597. https://doi.org/10.1023/A:1008307528519
Savage, D. G. ; Rule, S. A.J. ; Tighe, M. ; Garrett, T. J. ; Oster, M. W. ; Lee, R. T. ; Ruiz, J. ; Heitjan, D. ; Keohan, M. L. ; Flamm, M. ; Johnson, S. A. / Gemcitabine for relapsed or resistant lymphoma. In: Annals of Oncology. 2000 ; Vol. 11, No. 5. pp. 595-597.
@article{cbf06777525441db9d887c8b61eb658a,
title = "Gemcitabine for relapsed or resistant lymphoma",
abstract = "Background: Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma. Patients and methods: Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma. Results: The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non- hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months. Conclusions: Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.",
keywords = "Gemcitabine, Hodgkin's disease, Non-Hodgkin's lymphoma",
author = "Savage, {D. G.} and Rule, {S. A.J.} and M. Tighe and Garrett, {T. J.} and Oster, {M. W.} and Lee, {R. T.} and J. Ruiz and D. Heitjan and Keohan, {M. L.} and M. Flamm and Johnson, {S. A.}",
year = "2000",
month = "7",
day = "15",
doi = "10.1023/A:1008307528519",
language = "English (US)",
volume = "11",
pages = "595--597",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Gemcitabine for relapsed or resistant lymphoma

AU - Savage, D. G.

AU - Rule, S. A.J.

AU - Tighe, M.

AU - Garrett, T. J.

AU - Oster, M. W.

AU - Lee, R. T.

AU - Ruiz, J.

AU - Heitjan, D.

AU - Keohan, M. L.

AU - Flamm, M.

AU - Johnson, S. A.

PY - 2000/7/15

Y1 - 2000/7/15

N2 - Background: Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma. Patients and methods: Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma. Results: The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non- hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months. Conclusions: Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.

AB - Background: Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma. Patients and methods: Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma. Results: The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non- hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months. Conclusions: Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.

KW - Gemcitabine

KW - Hodgkin's disease

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0033919922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033919922&partnerID=8YFLogxK

U2 - 10.1023/A:1008307528519

DO - 10.1023/A:1008307528519

M3 - Article

VL - 11

SP - 595

EP - 597

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -